A Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) and HER2 Exon 20 Mutant NSCLC

Trial Profile

A Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) and HER2 Exon 20 Mutant NSCLC

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Poziotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Apr 2018 According to a Spectrum Pharmaceuticals media release, at this point, the original cohort of 30 EGFR patients is fully enrolled and the expanded cohort of 20 patients is nearing the completion of enrollment. As enrollment in this study nears completion, patient enrolling will begin soon in the ongoing Spectrums multicenter Phase 2 study (NCT03318939).
    • 10 Apr 2018 According to a Spectrum Pharmaceuticals media release, the comprehensive data from this study will be presented at a major medical meeting later this year.
    • 10 Apr 2018 Updated data based on longer follow-up from this trial in patients with EGFR Exon 20 mutant non-small cell lung cancer, presented in a Spectrum Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top